• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用乘法强度模型进行两样本问题的样本量计算。

Sample size calculations for the two-sample problem using the multiplicative intensity model.

作者信息

Bernardo M V, Harrington D P

机构信息

Department of Biostatistics, Harvard School of Public Health, USA.

出版信息

Stat Med. 2001 Feb 28;20(4):557-79. doi: 10.1002/sim.693.

DOI:10.1002/sim.693
PMID:11223901
Abstract

In this paper we propose formulae for calculating the expected number of events or, alternatively, the required trial duration, for clinical trials involving two treatment groups in which patients may potentially experience multiple events and the data will be analysed using a multiplicative intensity (MI) model. We use a partial likelihood-based approach and examine in detail two MI models: one that includes a binary treatment variable as the only covariate and a three-state Markov process model in which a binary time-varying covariate is added to the previous model. For the simpler model, our formula coincides with those derived by Cook using full likelihood methods. We present applications of the derived formulae to chronic granulomatous disease and breast cancer data sets.

摘要

在本文中,我们提出了用于计算预期事件数的公式,或者,对于涉及两个治疗组的临床试验,计算所需的试验持续时间的公式。在这些试验中,患者可能会经历多个事件,并且将使用乘性强度(MI)模型对数据进行分析。我们采用基于部分似然的方法,并详细研究了两个MI模型:一个模型将二元治疗变量作为唯一协变量,另一个是三状态马尔可夫过程模型,其中在前一个模型中添加了一个二元时变协变量。对于较简单的模型,我们的公式与库克使用全似然方法得出的公式一致。我们展示了所推导公式在慢性肉芽肿病和乳腺癌数据集上的应用。

相似文献

1
Sample size calculations for the two-sample problem using the multiplicative intensity model.使用乘法强度模型进行两样本问题的样本量计算。
Stat Med. 2001 Feb 28;20(4):557-79. doi: 10.1002/sim.693.
2
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.环磷酰胺、甲氨蝶呤、5-氟尿嘧啶、长春新碱和泼尼松辅助化疗与单药左旋苯丙氨酸氮芥治疗可手术乳腺癌且腋窝淋巴结阳性患者的比较:西南肿瘤协作组20年研究结果
Cancer. 2003 Jan 1;97(1):21-9. doi: 10.1002/cncr.10982.
3
Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.他莫昔芬与辅助性风险适应性化疗后绝经后、受体阴性乳腺癌患者对照:一项随机试验(GABG-IV D-93)——德国辅助性乳腺癌研究组
J Clin Oncol. 2005 Nov 1;23(31):7842-8. doi: 10.1200/JCO.2005.01.3433.
4
Evidence from nonrandomized studies: a case study on the estimation of causal effects.非随机研究的证据:因果效应估计的案例研究
Am J Epidemiol. 2008 May 1;167(9):1120-9. doi: 10.1093/aje/kwn010. Epub 2008 Mar 11.
5
Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.确定腋窝淋巴结1 - 3个阳性的乳腺癌患者中可从辅助性环磷酰胺、甲氨蝶呤和5 - 氟尿嘧啶(CMF)化疗中获益的预后良好组。
Jpn J Clin Oncol. 2005 Sep;35(9):514-9. doi: 10.1093/jjco/hyi143.
6
Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.环磷酰胺、甲氨蝶呤和氟尿嘧啶与环磷酰胺、多柔比星和氟尿嘧啶联合或不联合他莫昔芬治疗高危、淋巴结阴性乳腺癌的随机对照试验:肿瘤协作组INT-0102治疗结果
J Clin Oncol. 2005 Nov 20;23(33):8313-21. doi: 10.1200/JCO.2005.08.071.
7
Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.接受乳房切除术及辅助化疗(使用或不使用他莫昔芬且未进行放疗)治疗的可手术乳腺癌患者的局部区域复发模式:五项国家外科辅助乳腺和肠道项目随机临床试验的结果
J Clin Oncol. 2004 Nov 1;22(21):4247-54. doi: 10.1200/JCO.2004.01.042. Epub 2004 Sep 27.
8
Sample size calculations for comparative clinical trials with over-dispersed Poisson process data.具有过度分散泊松过程数据的比较临床试验的样本量计算。
Stat Med. 2005 May 15;24(9):1339-56. doi: 10.1002/sim.2011.
9
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.HER-2扩增和拓扑异构酶IIα基因畸变作为预测标志物,用于接受蒽环类药物为基础的治疗或环磷酰胺、甲氨蝶呤和5-氟尿嘧啶随机治疗的淋巴结阳性乳腺癌患者。
Clin Cancer Res. 2002 May;8(5):1107-16.
10
Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.优化绝经后乳腺癌治疗模式:FACE试验
Expert Rev Anticancer Ther. 2006 Oct;6(10):1355-9. doi: 10.1586/14737140.6.10.1355.

引用本文的文献

1
The effect of omitted covariates in marginal and partially conditional recurrent event analyses.边际和部分条件复发事件分析中遗漏协变量的影响。
Lifetime Data Anal. 2019 Apr;25(2):280-300. doi: 10.1007/s10985-018-9430-y. Epub 2018 May 16.
2
Simulating recurrent event data with hazard functions defined on a total time scale.使用在总时间尺度上定义的风险函数模拟复发事件数据。
BMC Med Res Methodol. 2015 Mar 8;15:16. doi: 10.1186/s12874-015-0005-2.
3
Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome.
用于复发事件数据的优效性临床试验的贝叶斯设计及其在骨髓增生异常综合征出血和输血事件中的应用
Biometrics. 2014 Dec;70(4):1003-13. doi: 10.1111/biom.12215. Epub 2014 Jul 16.
4
Robust covariate-adjusted log-rank statistics and corresponding sample size formula for recurrent events data.针对复发事件数据的稳健协变量调整对数秩统计量及相应样本量公式。
Biometrics. 2008 Sep;64(3):741-750. doi: 10.1111/j.1541-0420.2007.00948.x. Epub 2007 Dec 5.